A Phase 1 interventional study of ACT500 tablets in Metabolic Dysfunction-associated Steatohepatitis, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Not yet recruiting at 4 sites in China. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Fatty Liver with a site in China — 30 open to participants now, 34 under way, 2 of them phase 3. Fatty Liver · China.
Among the 63 studies in Fatty Liver with a site in China, this one is the 35th largest by planned enrollment of the 37 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 15 of the 33 other live ones, and was the 55th registered.
663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.
Browse Fatty Liver studies →30 of the 63 studies in Fatty Liver with a site in China are open now. Recruiting first, the newest first:
Li Lab,MD · Sites in China
Ages 18–74
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–60
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hudson Biotech · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 4 · Phase 4 4
First in 2004; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 60 across 432 interventional studies indexed under Fatty Liver.
Median enrollment 90 across the 37 interventional studies, 400 across the 26 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 63 have an industry lead sponsor. The 10 most frequent:
Xiamen Amoytop Biotech Co., Ltd. is the lead sponsor of 32 studies on the registry; 12 are open to participants now.
Xiamen Amoytop Biotech Co., Ltd. has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
9 of the studies in Fatty Liver with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268262The Affiliated Hospital of Xuzhou Medical UniversitySurgical-imaging Research on Obesity (SIRO) | 2026-12 |
| NCT05974904Chongqing Medical UniversityAssociation of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study | 2026-12-28 |
| NCT07481734Hudson BiotechTesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | 2027-02-14 |
| NCT07462455Xiamen Amoytop Biotech Co., Ltd.Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) | 2027-02-28 |
| NCT07807059Fujian Shengdi Pharmaceutical Co., Ltd.A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment | 2027-03-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 63 studies in Fatty Liver with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, open-label, dose-escalation trial designed to evaluate the safety, tolerability, PK, and PD profiles of ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial plans to enroll approximately 24 MASLD participants across four dose cohorts, each consisting of 6 participants who will receive oral ACT500 once daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of at least one of the following metabolic risk factors:
Both male and female participants must agree to use appropriate methods, as follows:
Exclusion Criteria:
[1] Combined with other liver diseases, including but not limited to , , drug-induced liver disease, alcoholic liver disease, liver disease, suspected or confirmed hepatocellular carcinoma, etc.
[2] Have a history of or currently have other , liver cirrhosis (including confirmed or suspected liver cirrhosis by imaging examination, or liver cirrhosis confirmed by liver ), or have evidence of decompensated liver disease (such as ascites, esophageal and gastric variceal bleeding, or hepatic encephalopathy, etc.), or have a history of liver transplantation.
[3] Have a history of or current symptoms of severe cardiovascular and cerebrovascular diseases, including but not limited to uncontrolled or severe arrhythmias (ventricular fibrillation, atrial fibrillation, etc.), myocardial infarction, coronary heart disease, etc.
[4] Have a history of persistent, respiratory, neurological, gastrointestinal, immunological, hematological, or psychiatric diseases, which, in the investigator's judgment, would pose additional risk to the participant.
[5] Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (fasting plasma glucose >9 mmol/L within 3 months prior to screening, or >9.5% at screening); or patients with diabetes receiving anti-hyperglycemic medications other than metformin and insulin.
[6] Have an estimated (eGFR) \<60 mL/min/1.73 m² at screening or a history of severe renal impairment.
[7] Have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia; or have \<105 g/L for female participants or \<115 g/L for male participants at screening; or any other condition known to interfere with hemoglobin measurement as judged by the investigator.
[8] Any of the following laboratory abnormalities at screening: alkaline phosphatase (ALP) >2× (ULN); total serum (TBIL) >1.5×ULN (excluding participants with benign unconjugated hyperbilirubinemia deemed eligible for enrollment by the Investigator, with total bilirubin \<2×ULN and direct bilirubin \<ULN); (INR) >1.3.
[9] Have had a body weight change (increase or decrease) of >5% within 3 months prior to screening, or have undergone dieting, bariatric surgery, or used medications approved for weight loss indications.
[10] Have a history of major trauma or surgery within 3 months prior to screening, or plan to undergo surgery during the study period.
[11] Have a history of excessive alcohol consumption for 3 consecutive months or more within 1 year prior to screening, defined as a weekly ethanol intake of ≥210 g for males and ≥140 g for females; or have a history of drug abuse/dependence or a history of illicit drug inhalation/injection within 1 year prior to screening.
[12] Have used medications that may have a therapeutic effect on MASLD/MASH (e.g., GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, FGF21 analogs, resmetirom, etc.) or medications that may cause MASLD/MASH (e.g., amiodarone, methotrexate, tetracyclines, tamoxifen, estrogens at doses greater than hormone replacement therapy, anabolic steroids, valproic acid, other known hepatotoxic drugs, etc.) within 3 months prior to screening, or other medications that the investigator considers may affect the trial.
[13] Have participated in another drug clinical trial within 3 months prior to screening.
[14]Positive antibody (HIV-Ab) at screening; or positive treponema pallidum antibody together with positive rapid plasma reagin (RPR) test (RPR shall only be performed when treponema pallidum antibody is positive).
[15] Have a known allergy to the of ACT500 or to drugs with a similar chemical structure to ACT500, or have other drug allergies that, in the investigator's judgment, preclude participation in the study.
[16] Have any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study, or are unable to participate in the trial due to the participant's own reasons after signing the form (ICF).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ACT500 tablets
Drug: ACT500 tablets
Drug: ACT500 tablets
Drug: ACT500 tablets
Once daily, orally
Adverse Event#AE#
Time frame: Day1-112
Serious Adverse Event
Time frame: Day1-112
body temperature
Time frame: Day 1,14,29,56,84,112
Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v6.0
Time frame: Day 1,14,29,56,84,112
pulse
Time frame: Day 1,14,29,56,84,112
heart rate
Time frame: Day 1,14,29,56,84,112
blood pressure
Time frame: Day 1,14,29,56,84,112
Number of Participants with Abnormal Laboratory Parameters Findings
Time frame: Day 1,14,29,56,84,112
Number of participants with clinically significant change from baseline in physical examination
Time frame: Day 1,14,29,56,84,112
Heart Rate
Time frame: Day 14,29,56,84,112,
PR Interval
Time frame: Day 14,29,56,84,112,
QRS Interval
Time frame: Day 14,29,56,84,112,
QT Interval
Time frame: Day 14,29,56,84,112,
QTc Interval
Time frame: Day 14,29,56,84,112,
Area Under Curve(0-t)
Time frame: Day 1,2,14,28,29
Area Under the Concentration-time curve from time zero to τ at steady state
Time frame: Day 1,2,14,28,29
Area Under Curve(0-∞)
Time frame: Day 1,2,14,28,29
Maximum Plasma Concentration
Time frame: Day 1,2,14,28,29
Time to Maximum (plasma) Concentration
Time frame: Day 1,2,14,28,29
Elimination Half-Life
Time frame: Day 1,2,14,28,29
CL/F
Time frame: Day 1,2,14,28,29
Apparent Volume of Distribution
Time frame: Day 1,2,14,28,29
Cmin,ss
Time frame: Day 1,2,14,28,29
Cav,ss
Time frame: Day 1,2,14,28,29
Rac_Cmax
Time frame: Day 1,2,14,28,29
Rac_AUC0-tau
Time frame: Day 1,2,14,28,29
DF
Time frame: Day 1,2,14,28,29
MRI-PDFF-determined liver fat content (LFC)
Time frame: Day 29,112
Fibroscan-measured liver stiffness measurement (LSM)
Time frame: Day 29,112
AST/PLT Ratio Index,APRI
Time frame: Day 1,14,29,56,84,112
absolute change from baseline in ELF
Time frame: Day 1,14,29,56,84,112
percent change from baseline in ELF
Time frame: Day 1,14,29,56,84,112
Total Cholesterol
Time frame: Day 1,14,29,56,84,112
Triglyceride
Time frame: Day 1,14,29,56,84,112
Low-Density Lipoprotein Cholesterol
Time frame: Day 1,14,29,56,84,112
High-Density Lipoprotein Cholesterol
Time frame: Day 1,14,29,56,84,112
apolipoprotein A1
Time frame: Day 1,14,29,56,84,112
apolipoprotein B
Time frame: Day 1,14,29,56,84,112
absolute change from baseline in lipoprotein(a)
Time frame: Day 1,14,29,56,84,112
percent change from baseline in lipoprotein(a)
Time frame: Day 1,14,29,56,84,112
Alanine Aminotransferase
Time frame: Day 1,14,29,56,84,112
Aspartate Aminotransferase
Time frame: Day 1,14,29,56,84,112
Gamma-Glutamyl Transferase(GGT)
Time frame: Day 1,14,29,56,84,112
absolute change from baseline in GGT
Time frame: Day 1,14,29,56,84,112
percent change from baseline in GGT
Time frame: Day 1,14,29,56,84,112
body weight
Time frame: Day 1,14,29,56,84,112
body Mass Index
Time frame: Day 1,14,29,56,84,112
waist circumference
Time frame: Day 1,14,29,56,84,112
absolute change from baseline in hip circumference
Time frame: Day 1,14,29,56,84,112
High-sensitivity C-reactive protein
Time frame: Day 1,2,14,28,29
Tumor Necrosis Factor alpha
Time frame: Day 1,2,14,28,29
Cytokeratin 18 (M30)
Time frame: Day 1,2,14,28,29
N-terminal propeptide of type III collagen (Pro-C3)
Time frame: Day 1,14,29
absolute change from baseline in Pro-C3
Time frame: Day 1,1429
percent change from baseline in Pro-C3
Time frame: Day 1,14,29
Insulin-like Growth Factors-1
Time frame: Day 1,14,29
Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)
Time frame: Day 1,29
absolute change from baseline in IGFBP-3
Time frame: Day 1,29
percent change from baseline in IGFBP-3
Time frame: Day 1,29
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2027, 3 months later.
Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ACT500
Xiamen Amoytop Biotech Co., Ltd. →